Kalaris Therapeutics, Inc.

Stage 4 · Declining · week 23

As of Oct 22, 2026, Kalaris Therapeutics is in Stage 4, the downtrend phase, now in week 23 (since May 15, 2026). It closed at $1.99, 81.9% below its 52-week high and below its 200-day average, which is falling.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. More about the company

$1.99

-1.49% today

$47.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is KLRS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 33w

S1 13w

S4 40w

S2 18w

S4 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 33w → S1 13w → S4 10w → S1 3w → S2 7w → S3 1w → S4 40w → S1 11w → S2 18w → S3 7w → S4 23w current

Total tracked: 165 weeks across 11 stage runs.

KLRS among Biotechnology395th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…395	KLRSKalaris Therapeutics, Inc.	Stage 4 · wk 23	19	−36.2%

vs 52W High

-81.9%

$1.91 lo$10.98 hi

81.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 23

1w13w26w

Week 23, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-64.6%

200 DMA: $5.62 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.60x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-36.2%

-46.6%

-67.4%

YTD

-76.0%

-57.9%

Scan Membership

Breakout Watch

Latest: 2024-10-07

2 appearances in last 60 days. First seen: 2022-09-28.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 23 · Vol 0.60x

2026-10-21S4

Wk 22 · Vol 1.16x

2026-10-20S4

Wk 22 · Vol 0.72x

2026-10-19S4

Wk 22 · Vol 4.07x

2026-10-16S4

Wk 22 · Vol 0.88x

2026-10-15S4

Wk 22 · Vol 0.86x

2026-10-14S4

Wk 21 · Vol 0.31x

2026-10-13S4

Wk 21 · Vol 1.05x

2026-10-12S4

Wk 21 · Vol 1.77x

2026-10-09S4

Wk 21 · Vol 1.53x

2026-10-08S4

Wk 21 · Vol 1.61x

2026-10-07S4

Wk 20 · Vol 1.07x

Moving averages & range

50 DMA

$3.20

200 DMA

$5.62

52W High

$10.98

52W Low

$1.91

5D Low

$1.91

Resistance levels (recent highs)

20d High

$2.92

60d High

$4.32

120d High

$5.53

250d High

$10.98

Next resistance

+46.7%

to 20d High

ROE

-79.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.8

Kalaris Therapeutics: quick answers

What stage is Kalaris Therapeutics in?

As of Oct 22, 2026, Kalaris Therapeutics (KLRS) is in Stage 4, the downtrend phase. It entered Stage 4 on May 15, 2026 and is in week 23. What the four stages mean

Is Kalaris Therapeutics in an uptrend?

No. Kalaris Therapeutics is in a Stage 4 downtrend. It trades 64.6% below its 200-day average, which is falling.

How far is Kalaris Therapeutics from its 52-week high?

Kalaris Therapeutics closed at $1.99 on Oct 22, 2026, 81.9% below its 52-week high of $10.98. Its 52-week low is $1.91.

How has Kalaris Therapeutics performed over the past year?

As of Oct 22, 2026, Kalaris Therapeutics is down 57.9% over the past year and down 76.0% so far in 2026.

Which sector and industry is Kalaris Therapeutics in?

Kalaris Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.